Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB)

Historical Holders from Q1 2019 to Q3 2025

Symbol: INMB on Nasdaq
Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 27,969,231
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares, excl. options: 4,653,422
Holdings value: $9,631,501
% of all portfolios: 0%
Number of holders: 72
Number of buys: 35
Number of sells: -45
Average buys %: +0%
Average sells %: -0%

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB)

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
HIGHBRIDGE CAPITAL MANAGEMENT LLC	5.2%		$3,359,664		1,454,400		Highbridge Capital Management, LLC	30 Jun 2025
CVI Investments, Inc.	4.9%	-10%	$3,225,404	-$239,596	1,396,279	-6.9%	CVI Investments, Inc.	30 Jun 2025
Praetorian PR LLC	3.4%	-54%	$2,127,972	-$1,700,160	921,200	-44%	Kupperman Harris	30 Jun 2025

Institutional Holders of Inmune Bio, Inc. - Common Stock, par value $0.001 per share (INMB)

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q3	4,653,422	$9,631,501	-$1,934,721	$769,509	$642,228	$2.07	72
2025 Q2	5,623,690	$12,725,267	-$10,010,248	$7,717,479	$3,662,392	$2.31	78
2025 Q1	6,162,475	$48,114,521	-$163,536	$808,644	$1,577,005	$7.81	81
2024 Q4	6,324,914	$29,538,643	+$2,163,001	$200,343	$944,741	$4.67	72
2024 Q3	5,352,153	$28,834,750	+$6,030,346	$250,096	$1,308,153	$5.39	65
2024 Q2	4,566,933	$40,279,815	+$15,412,868	$368,676	$705,600	$8.82	56
2024 Q1	2,738,821	$32,179,382	+$5,308,168	$41,125	$524,050	$11.75	50
2023 Q4	2,292,004	$25,807,938	+$1,854,241	$298,390	$613,670	$11.26	47
2023 Q3	2,133,529	$14,477,326	-$5,887,298	$307,800	$249,320	$6.77	36
2023 Q2	2,186,070	$24,850,986	+$8,529,775	$340,500	$366,033	$9.08	32
2023 Q1	1,804,387	$11,657,371	+$1,101,433	$13,566	$103,360	$6.46	33
2022 Q4	1,645,407	$10,430,707	-$728,047	$102,074	$332,850	$6.34	32
2022 Q3	1,912,551	$11,855,780	-$744,186	$122,000	$313,000	$6.2	32
2022 Q2	2,010,894	$17,633,536	-$2,412,787	$0	$433,000	$8.84	34
2022 Q1	2,294,234	$19,315,368	-$2,106,118	$208,000	$243,000	$8.42	32
2021 Q4	2,484,556	$25,343,080	+$4,757,601	$390,000	$461,000	$10.2	42
2021 Q3	1,942,445	$37,703,608	+$4,889,864	$2,653,000	$2,701,000	$19.42	40
2021 Q2	1,710,752	$30,053,028	+$8,038,213	$894,000	$973,000	$17.57	39
2021 Q1	1,305,763	$15,492,692	+$5,444,483			$11.88	32
2020 Q4	793,136	$13,655,776	+$1,189,170			$17.21	25
2020 Q3	992,741	$10,252,248	+$6,463,618			$10.3	27
2020 Q2	358,561	$1,881,000	+$104,639			$5.17	11
2020 Q1	342,213	$1,139,000	+$200,616			$3.32	9
2019 Q4	282,367	$1,637,000	+$40,401			$5.8	9
2019 Q3	274,538	$1,620,000	+$1,390,869			$5.9	9
2019 Q2	38,466	$373,000	-$43,981			$9.72	7
2019 Q1	45,117	$352,000	+$352,000			$7.44	5